Skandinaviska Enskilda Banken AB publ Grows Stake in Edwards Lifesciences Co. (NYSE:EW)

Skandinaviska Enskilda Banken AB publ lifted its stake in Edwards Lifesciences Co. (NYSE:EW) by 6.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 949,074 shares of the medical research company’s stock after buying an additional 56,051 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Edwards Lifesciences were worth $70,459,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of EW. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Edwards Lifesciences in the 4th quarter worth approximately $30,000. FSA Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the third quarter worth $30,000. Prospera Private Wealth LLC purchased a new position in shares of Edwards Lifesciences in the third quarter valued at $32,000. Avior Wealth Management LLC grew its holdings in Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares in the last quarter. Finally, Roble Belko & Company Inc acquired a new stake in Edwards Lifesciences during the 4th quarter valued at $46,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bernard J. Zovighian sold 6,164 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.51, for a total value of $428,459.64. Following the completion of the sale, the chief executive officer now owns 59,083 shares of the company’s stock, valued at $4,106,859.33. This trade represents a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 44,303 shares of company stock worth $3,255,356. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of EW opened at $68.52 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a market cap of $40.28 billion, a P/E ratio of 9.83, a PEG ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The stock has a fifty day moving average price of $71.92 and a 200 day moving average price of $70.34.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, research analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

EW has been the subject of a number of analyst reports. Evercore ISI decreased their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research report on Wednesday, February 12th. Citigroup raised their price objective on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Piper Sandler upped their target price on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Truist Financial reissued a “hold” rating and set a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $85.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.